{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:44:51Z","timestamp":1787697891586,"version":"build-2784847793"},"reference-count":36,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T00:00:00Z","timestamp":1570492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["CSC No. 201706370238"],"award-info":[{"award-number":["CSC No. 201706370238"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2020,1,15]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The role of radiotherapy (RT) in the treatment of patients with anaplastic thyroid cancer (ATC) for local tumor control is critical because mortality often is secondary to complications of tumor volume rather than metastatic disease. Herein, the authors report the long\u2010term outcomes of RT for patients with ATC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 104 patients with histologically confirmed ATC were identified who presented to the study institution between 1984 and 2017 and who received curative\u2010intent or postoperative RT. Locoregional progression\u2010free survival (LPFS), overall survival (OS), and distant metastasis\u2013free survival were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age of the patients was 63.5\u00a0years. The median follow\u2010up was 5.9\u00a0months (interquartile range, 2.7\u201017.0\u00a0months) for the entire cohort and 10.6\u00a0months (interquartile range, 5.3\u201040.0\u00a0months) for surviving patients. Thirty\u2010one patients (29.8%) had metastatic disease prior to the initiation of RT. Concurrent chemoradiation was administered in 99 patients (95.2%) and 53 patients (51.0%) received trimodal therapy. Systemic therapy included doxorubicin (73.7%), paclitaxel with or without pazopanib (24.3%), and other systemic agents (2.0%). The 1\u2010year OS and LPFS rates were 34.4% and 74.4%, respectively. On multivariate analysis, RT \u226560 Gy was associated with improved LPFS (hazard ratio [HR], 0.135; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.001) and improved OS (HR, 0.487; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.004), and trimodal therapy was associated with improved LPFS (HR, 0.060; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.017). The most commonly observed acute grade 3 adverse events included dermatitis (20%) and mucositis (13%), with no grade 4 subacute or late adverse events noted (adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events [version 4.0]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>RT appears to demonstrate a dose\u2010dependent, persistent LPFS and OS benefit in patients with locally advanced ATC with an acceptable toxicity profile. Aggressive RT should be strongly considered for the treatment of patients with ATC as part of a trimodal treatment approach.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.32548","type":"journal-article","created":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T11:01:30Z","timestamp":1570532490000},"page":"444-452","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer"],"prefix":"10.1002","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1197-1737","authenticated-orcid":false,"given":"Dan","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology Xiangya Hospital Central South University Changsha Hunan China"},{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Bell","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andries H.","family":"Groen","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology University Medical Center Groningen University of Groningen Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyrie S.","family":"Olsen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin H.","family":"Lok","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York"},{"name":"Department of Radiation Oncology Princess Margaret Hospital Cancer Centre Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4539-0762","authenticated-orcid":false,"given":"Jonathan E.","family":"Leeman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York"},{"name":"Department of Radiation Oncology Brigham and Women's Hospital Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem","family":"Riaz","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"McBride","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Ganly","sequence":"additional","affiliation":[{"name":"Department of Surgery Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok R.","family":"Shaha","sequence":"additional","affiliation":[{"name":"Department of Surgery Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4960-4783","authenticated-orcid":false,"given":"Eric J.","family":"Sherman","sequence":"additional","affiliation":[{"name":"Department of Medicine Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Jillian","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung J.","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,10,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0302"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008322002520"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2012.00084"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2012.53.2.352"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20936"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2006.05.042"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.09.004"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010615)91:12<2335::AID-CNCR1266>3.0.CO;2-1"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19871115)60:10<2372::AID-CNCR2820601004>3.0.CO;2-1"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830915)52:6<954::AID-CNCR2820520603>3.0.CO;2-D"},{"key":"e_1_2_8_12_1","unstructured":"ClinicalTrials.gov.Pembrolizumab chemotherapy and radiation therapy with or without surgery in treating patients with anaplastic thyroid cancer. Published July 7 2017. Updated May 1 2018. Accessed October 5 2018.https:\/\/ClinicalTrials.gov\/show\/NCT03211117"},{"key":"e_1_2_8_13_1","unstructured":"ClinicalTrials.gov.Atezolizumab with chemotherapy in treating patients with anaplastic or poorly differentiated thyroid cancer. Published June 8 2017. Updated July 24 2018. Accessed October 5 2018.https:\/\/ClinicalTrials.gov\/show\/NCT03181100"},{"key":"e_1_2_8_14_1","unstructured":"ClinicalTrials.gov.Pembrolizumab in anaplastic\/undifferentiated thyroid cancer. Published February 23 2016. Updated November 20 2017. Accessed October 5 2018.https:\/\/ClinicalTrials.gov\/show\/NCT02688608"},{"key":"e_1_2_8_15_1","unstructured":"ClinicalTrials.gov.Inolitazone dihydrochloride and paclitaxel in treating patients with advanced anaplastic thyroid cancer. Published June 2 2014. Updated September 6 2018. Accessed October 5 2018.https:\/\/ClinicalTrials.gov\/show\/NCT02152137"},{"key":"e_1_2_8_16_1","unstructured":"ClinicalTrials.gov.A Phase 2 trial of lenvatinib for the treatment of anaplastic thyroid cancer (ATC). Published January 15 2016. Updated November 7 2017. Accessed October 5 2018.https:\/\/ClinicalTrials.gov\/show\/NCT02657369"},{"key":"e_1_2_8_17_1","unstructured":"ClinicalTrials.gov.A phase II study of MLN0128 in metastatic anaplastic thyroid cancer. Published September 19 2014. Accessed October 5 2018.https:\/\/ClinicalTrials.gov\/show\/NCT02244463"},{"key":"e_1_2_8_18_1","unstructured":"ClinicalTrials.gov.Phase II study assessing the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE). Published April 1 2016. Updated June 2 2017. Accessed October 5 2018.https:\/\/ClinicalTrials.gov\/show\/NCT02726503"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0395"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(01)00382-6"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(03)00405-X"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(00)00621-0"},{"key":"e_1_2_8_23_1","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03","author":"National Cancer Institute, National Institutes of Health, US Department of Health and Human Services","year":"2010"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2014.12.006"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0095"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A5487"},{"key":"e_1_2_8_28_1","unstructured":"National Comprehensive Cancer Network.NCCN Guidelines thyroid carcinoma\u2013anaplastic carcinoma (version 1.2018). Published2018. Accessed October 5 2018.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/thyroid.pdf"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2012.03.010"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3545-5"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-008-0005-0"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.05.032"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01180"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.0220"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30493"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85271"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198506203122504"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.32548","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.32548","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.32548","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.32548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:45:22Z","timestamp":1760276722000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.32548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,8]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,1,15]]}},"alternative-id":["10.1002\/cncr.32548"],"URL":"https:\/\/doi.org\/10.1002\/cncr.32548","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,8]]},"assertion":[{"value":"2019-01-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}